Core Insights - Arrowhead has reported significant efficacy data for its weight-loss small nucleic acid drugs, particularly ARO-INHBE, which achieved a 9.4% weight reduction in obese patients with type 2 diabetes when combined with tirzepatide, nearly double the 4.8% reduction seen with tirzepatide alone [2] - The small nucleic acid drug sector is experiencing rapid advancements, transitioning from concept validation to a pre-industrial rise, with expectations for a "golden development period" driven by technological breakthroughs and commercial realization [2] - The valuation of innovative drug assets is undergoing continuous recovery, with an increasing number of domestic original drugs being approved, leading to market capture across various therapeutic areas [2] Industry Trends - The small nucleic acid drug industry is expected to expand significantly by 2025, with advancements in delivery technologies allowing for broader applications beyond the liver to cardiovascular and CNS areas [2] - The commercialization of major products and substantial mergers and acquisitions by multinational pharmaceutical giants are anticipated to further drive industry growth [2] - The innovative drug sector is witnessing a surge in overseas licensing deals, contributing to the growth momentum of the sector [2] Investment Opportunities - The innovative drug sector in China is projected to have long-term development potential, with short-term focus on themes like brain-computer interfaces and small nucleic acids [5] - Key upcoming conferences, such as the JPM conference in January and the ASCO annual meeting in May, are expected to disclose critical clinical data, enhancing the performance of commercialized companies [5] - The ETF focusing on innovative drugs, 国泰 (589720), has shown a performance advantage over Hong Kong's innovative drug sector, with a nearly 10% lead since the 2024 "924 market" [5][6]